Published in final edited form as:

Cell Mol Life Sci. 2013 September ; 70(17): 3199–3210. doi:10.1007/s00018-013-1311-7.

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation

Takashi Angata,

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan; Graduate School of Medicine, Osaka University, 1-3 Yamadaoka, Suita, Osaka 565-0871, Japan

Takeo Ishii,

Respiratory Care Clinic, Nippon Medical School, 4-7-15-8F Kudan-Minami, Chiyoda, Tokyo 102-0074, Japan; Division of Pulmonary Medicine, Infectious Diseases and Oncology, Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 113-8602, Japan

Takashi Motegi,

Respiratory Care Clinic, Nippon Medical School, 4-7-15-8F Kudan-Minami, Chiyoda, Tokyo 102-0074, Japan; Division of Pulmonary Medicine, Infectious Diseases and Oncology, Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 113-8602, Japan

Ritsuko Oka,

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Rachel E. Taylor,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA

Paula Campos Soto,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA

Yung-Chi Chang,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Pediatrics, University of California at San Diego, La Jolla, CA 92093-0687, USA

© springer Basel 2013

Correspondence to: Takashi Angata; Kozui Kida; Naoyuki Taniguchi.

angata@riken.jp, tani52@wd5.so-net.ne.jp, kkida@nms.ac.jp.

T. Angata and T. Ishii contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s00018-013-1311-7) contains supplementary material, which is available to authorized users.

Conflict of interest The authors declare that they have no conflict of interest.

Present Address: R. E. Taylor, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA

Ismael Secundino,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Pediatrics, University of California at San Diego, La Jolla, CA 92093-0687, USA

Cong-Xiao Gao,

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Kazuaki Ohtsubo,

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Shinobu Kitazume,

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Victor Nizet,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Pediatrics, University of California at San Diego, La Jolla, CA 92093-0687, USA

Ajit Varki,

Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA; Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA

Akihiko Gemma,

Division of Pulmonary Medicine, Infectious Diseases and Oncology, Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 113-8602, Japan

Kozui Kida, and

Respiratory Care Clinic, Nippon Medical School, 4-7-15-8F Kudan-Minami, Chiyoda, Tokyo 102-0074, Japan; Division of Pulmonary Medicine, Infectious Diseases and Oncology, Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 113-8602, Japan

Naoyuki Taniguchi

Systems Glycobiology Research Group, and RIKEN-Max Planck Joint Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide. COPD exacerbation, or episodic worsening of symptoms, often results in hospitalization and increased mortality rates. Airway infections by new bacterial strains, such as nontypeable *Haemophilus influenzae* (NTHi), are a major cause of COPD exacerbation. NTHi express lipooligosaccharides that contain sialic acids, and may interact with Siglec-14, a sialic acid recognition protein on myeloid cells that serves as an activating signal transduction receptor. A null allele polymorphism in *SIGLEC14* may attenuate the inflammatory responses to NTHi by eliminating Siglec-14 expression. We asked if the loss of Siglec-14 attenuates the inflammatory response by myeloid cells against NTHi, and if the *SIGLEC14*-null polymorphism has any effect on COPD exacerbation. We found that NTHi interacts with Siglec-14 to enhance proinflammatory cytokine production in a tissue culture model. Inhibitors of the Syk tyrosine kinase suppress this response. Loss of Siglec-14, due to *SIGLEC14*-null allele homozygosity, is associated with a reduced risk of COPD exacerbation in a Japanese patient population. Taken together, Siglec-14 and its

downstream signaling pathway facilitate the “infection–inflammation–exacerbation” axis of COPD disease progression, and may represent promising targets for therapeutic intervention.

Keywords

Siglec; Sialic acids; *Haemophilus influenzae*; Chronic obstructive pulmonary disease; Exacerbation

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible [1], and is projected to be the third leading cause of mortality in the world by 2030 [2]. Stable COPD is managed by a combination of pharmaceutical treatments, smoking cessation, and pulmonary rehabilitation. However, COPD exacerbation often results in hospitalization and increased patient mortality, and therefore account for a major proportion of the clinical and socioeconomic burden of the disease [3-5]. Acquisition of new bacterial strains that colonize airways often trigger COPD exacerbation, which in turn leads to disease progression [6, 7]. While vaccination can reduce the risk of certain infectious triggers, treatment options for exacerbations are limited, and thus new therapies would be of great value [8].

Studies of genetic polymorphisms and disease susceptibility often yield clues to new treatment approaches [9, 10]. While there are many reports correlating genetic polymorphisms and COPD susceptibility [11-15], those examining exacerbations are more limited [16-20]. A recent study has shown that a subgroup of patients appears to be particularly susceptible to exacerbation, and that this frequent-exacerbation phenotype is relatively stable [21], suggesting the presence of contributing genetic factor(s). Given that bacterial airway infections play a major role in COPD exacerbation [6, 7], one potentially fruitful avenue is to explore correlations between COPD exacerbations and genetic polymorphisms of proteins involved in bacterial recognition.

Nontypeable *Haemophilus influenzae* (NTHi), a Gram-negative bacterial pathogen considered a major cause of COPD exacerbation [6], expresses lipooligosaccharides that contain sialic acids [22, 23]. Sialic acids are acidic sugars commonly found on terminal positions of vertebrate glycans, but only occasionally in pathogenic bacteria [24]. Siglecs are a family of sialic acid-binding lectins expressed mainly on innate immune cells [25, 26]. Siglec-14, a family member with an activating signaling property, is expressed on granulocytes and monocytes, while Siglec-5, an inhibitory counterpart with extensive sequence identity to Siglec-14 (over 250 amino acids at the N-terminus), is found on granulocytes and B-lymphocytes [27, 28]. In humans, the ancestral (wildtype) *SIGLEC* gene cluster has both *SIGLEC14* and *SIGLEC5* genes in tandem, while a derived (*SIGLEC14*-null) allele harbors a single *SIGLEC14/5* fusion gene. The product of this fusion gene is identical to that of the wildtype *SIGLEC5* gene at the amino acid level [28]. We speculated that loss of Siglec-14 could result in attenuated immune responses against pathogenic bacteria that express sialic acids [28]. However, this possibility has not been formally tested.

In this work, we asked if Siglec-14 expression would alter the inflammatory response of myeloid cells elicited by NTHi, and if the *SIGLEC14*-null polymorphism is associated with altered risk of COPD exacerbation. We demonstrated that NTHi interacts with Siglec-14 to enhance production of proinflammatory cytokines in a tissue culture model, and that the loss of Siglec-14, due to *SIGLEC14*-null allele homozygosity, is associated with reduced risk of

COPD exacerbation. Based on these findings, we propose that Siglec-14 and its downstream signaling pathway may contain promising targets for therapeutic intervention.

Materials and methods

Study Subjects

Healthy volunteers were recruited at the University of California, San Diego, for Siglec expression analysis. Protocols for sample collection, genotyping, and related analyses were approved by the Institutional Review Board (IRB) at the University. Written informed consent was obtained from each donor.

For the analysis of correlations between *SIGLEC14* genotype and clinical phenotypes, outpatients who visited the Respiratory Care Clinic, Nippon Medical School, and had a diagnosis of COPD according to the global initiative for chronic obstructive lung disease (GOLD) criteria [1] were invited to participate in the study. The patients were current or ex-smokers with current symptoms compatible with COPD (e.g., dyspnea during exertion, prolonged coughing, or sputum) and air-flow limitation assessed by a pulmonary function test (post-bronchodilator forced expiratory volume in 1 s/forced vital capacity, FEV1/FVC, <70 %). Protocols for sample collection, genotyping, and related analyses were approved by the IRB at Nippon Medical School. Written informed consent was obtained from each donor.

Genotyping

Genotyping of the *SIGLEC14* locus was performed as described previously [28]. In brief, a set of three PCR reactions, specifically amplifying (1) *SIGLEC14*, (2) *SIGLEC5*, and (3) *SIGLEC14/5* fusion genes, were run in parallel using genomic DNA from each donor as template. Primer sequences and PCR conditions are provided in the Electronic supplementary material. The genotype of each donor was determined based on the patterns of amplification: genomic DNA from homozygous wildtype individuals yields products in reactions 1 and 2 but not in reaction 3 (+/+/-); that from heterozygous individuals yields products in all three reactions (+/+/+); and that from homozygous null individuals yields product only in reaction (3) (-/-/+).

Siglec expression analysis

Peripheral blood leukocytes were collected from healthy volunteers at the University of California, San Diego. Leukocytes were prepared by erythrocyte lysis using ACK lysing buffer, and stained with allophycocyanin-labeled anti-Siglec-5/14 antibody (FAB10721A) or control antibody (IC002A; both R&D systems, Minneapolis, MN) and AlexaFluor488-labeled anti-CD19 antibody (557697; BD Biosciences Pharmingen, San Diego, CA), and analyzed with a flow cytometer (FACSCalibur; BD Biosciences Immunocytometry Systems, San Jose, CA).

NTHi binding to Siglecs

NTHi (strain 2019) cultured in minimal medium not supplemented or supplemented with *N*-acetylneuraminic acid (0.5 mM) was prepared as described previously [29,30], heat-killed, and stored frozen until use. The bacteria (1.5×10^9 CFU) were labeled with fluorescein isothiocyanate (50 µg/ml in Dulbecco's phosphate-buffered saline, D-PBS) for 2 h at room temperature, washed, and suspended in 3 ml of assay buffer (1 % bovine serum albumin, BSA, in D-PBS). Recombinant Siglec-Fc fusion proteins were prepared as described previously [27]. A 96-well plate was coated overnight with protein A (0.5 µg/well in 50 mM sodium bicarbonate buffer, pH 9.5) at 4 °C. Subsequent incubations were carried out at room temperature. The protein A-coated plate was blocked with assay buffer, incubated with

Siglec-Fc (0.5 µg/well in assay buffer) for 2 h, washed, and incubated with 100 µl (5×10^7 CFU) per well of labeled NTHi for 2 h. The wells were washed, and fluorescence was measured with a fluorescent microplate reader (excitation 490 nm, emission 530 nm; MTP-650FA, Corona Electrics, Hitachinaka, Japan).

Assays for NTHi-induced proinflammatory cytokine responses

The THP-1 sublines expressing Siglec-5 or Siglec-14 were prepared as described previously [27]. The subline expressing both Siglec-5 and Siglec-14 was prepared by retroviral transduction of a Siglec-14⁺ subline with Siglec-5/pMSCVpuro packaged using the PLAT-A cell line [31]. The THP-1 sublines (1×10^6 /ml, 0.5 ml/well of 24-well plate) in Macrophage-SFM (Life Technologies, Carlsbad, CA) were mixed with 5×10^6 CFU of heat-killed NTHi (multiplicity of infection 10) and incubated for 24 h. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to quantify TNF-α (human TNF-α Quantikine HS ELISA kit; R&D Systems, Minneapolis, MN) and IL-8 (BD OptEIA human IL-8 ELISA set; BD Biosciences Pharmingen, San Diego, CA) in the culture supernatant.

In experiments investigating Syk inhibitors, the cells were preincubated with the inhibitors R406 (Selleck Chemicals, Houston, TX) or BAY61-3606 (Merck KGaA, Darmstadt, Germany) at various concentrations for 2 h before adding NTHi.

COPD patient populations

Outpatients who visited the Respiratory Care Clinic in November 2008 and had a diagnosis of COPD according to the GOLD criteria [1] were invited to participate in this longitudinal study. All subjects with obvious other pulmonary comorbidities were excluded. Written informed consent was obtained from each patient. Enrolled patients were carefully interviewed about the frequency of exacerbations every month for 1 year. We defined exacerbation in the following two ways: (1) using the classic definition of Anthonisen et al. [32], to determine the frequency of relatively severe exacerbations; and (2) using the new definition of Rodriguez-Roisin [33], to determine the frequency of mild and severe exacerbations.

Paired serum samples were collected from 21 COPD patients (age 71.0 ± 8.2 years; 19 men and 2 women; including six current smokers) seen both during a stable state and during exacerbations. A stable state was 8 weeks free from an exacerbation by the criteria of Anthonisen et al. [32]. Exacerbation sampling was only performed in patients who had not received prior oral corticosteroids and/or antibiotics.

Pulmonary function parameters

Post-bronchodilator FEV1, carbon monoxide-diffusing capacity (diffusing capacity divided by alveolar volume), vital capacity (VC), and FVC were measured according to the American Thoracic Society guidelines [34] using equipment for lung function testing (CHESTAC; CHEST Co., Tokyo, Japan). We used the reference values for post-bronchodilator FEV1 and VC specified by the Japanese Respiratory Society [35].

High-resolution computed tomography parameters

The percentage low attenuation area (LAA %) reflects the severity of emphysema. We performed helical high-resolution computed tomography scans at 1.25 mm collimation, 0.8 s scan time (rotation time), 120 kV and 100–600 mA with a LightSpeed Pro16 CT scanner (GE Company, Tokyo, Japan). LAA % was calculated as described previously [36–38].

Enzyme-linked immunosorbent assay for soluble Siglec-14

A mouse monoclonal antibody against human Siglec-14 (clone 40-1) was raised as described previously [28], and was provided by the National Institute of Advanced Industrial Science and Technology (Tsukuba, Ibaraki, Japan). Antibody (1 mg) was labeled with biotin using a commercial kit (biotin protein labeling kit; Roche Applied Science, Mannheim, Germany). All of the following procedures were carried out at room temperature. A 96-well plate was coated overnight with anti-Siglec-5/14 antibody (clone 194128; R&D Systems, Minneapolis, MN; 1 µg/ml in D-PBS, 100 µl/well), washed three times with 400 µl wash buffer (0.05 % Tween 20 in D-PBS) per well, blocked with 300 µl/well of assay buffer (1 % BSA in D-PBS) for 1 h, and washed three times. Serum samples (diluted 20 times with assay buffer) were added to the prepared wells and incubated for 2 h, and removed by aspiration. Wells were washed three times, incubated with biotinylated antibody against Siglec-14 for 2 h (0.5 µg/ml in assay buffer, 100 µl/well), washed, further incubated with streptavidin-conjugated horseradish peroxidase for 20 min (RPN1231V; GE Healthcare, Piscataway, NJ; diluted 1:1,000 in assay buffer, 100 µl/well), and washed. Finally, peroxidase substrate (SureBlue Reserve TMB 1-Component Microwell Peroxidase Substrate; Kirkegaard and Perry Laboratories, Gaithersburg, MD; 0.1 ml/well) was added to the wells and incubated for 15 min, and color development was stopped by adding 0.1 ml/well 1 N HCl. Absorbance at 450 nm was measured using a Model 680 microplate reader (Bio-Rad, Hercules, CA).

Statistical analyses

Statistical analyses of in vitro assays were performed using GraphPad Prism 4 (GraphPad Software, La Jolla, CA). Values were compared between two groups using an unpaired *t* test (or by a paired *t* test for paired samples), and those among three or more groups were compared by analysis of variance (ANOVA) followed by appropriate post-tests (as specified in the figure legends). Statistical analyses on patients were performed using JMP Genomics software version 5.1 (SAS Institute, Cary, NC). The effect of the *SIGLEC14* genotype on the incidence of bacterial exacerbation was analyzed by logistic regression, and that on the frequency of all exacerbations was analyzed by a Poisson regression with additive models on the wildtype (*SIGLEC14*-positive) allele. The generalized linear models that maximized the likelihood, and thus fit best, were considered appropriate. Age and gender were used as covariates, and smoking status, usage of inhaled corticosteroid, and post-bronchodilator FEV1 % predicted were also used as covariates when appropriate. Since separation can occur with relatively small datasets with many covariates, Firth's bias reduction was applied to the regression [39].

Results

SIGLEC14 genotype determines Siglec-5 and Siglec-14 expression on monocytes

We have previously reported that while Siglec-14 (activating-type signal transduction molecule) is expressed on granulocytes and monocytes, Siglec-5 (inhibitory counterpart) is found on granulocytes and B-lymphocytes [28] (Electronic supplementary material, Fig. 1a). In humans, the ancestral (wildtype) *SIGLEC* gene cluster has both *SIGLEC14* and *SIGLEC5* genes in tandem, while a derived (*SIGLEC14*-null) allele harbors a single *SIGLEC14/5* fusion gene, whose product is identical in amino acid sequence to that of wildtype *SIGLEC5* [28] (Electronic Supplementary Material, Fig. 1b). Since the 5'-upstream region of the *SIGLEC14/5* fusion gene is derived from *SIGLEC14*, we speculated that expression of the fusion gene product might parallel that of Siglec-14. Indeed, by analyzing Siglec-14-null individuals who are homozygous for the *SIGLEC14/5* fusion gene (i.e., homozygous *SIGLEC14*-null), we found that the fusion gene product is expressed not only on granulocytes and B-lymphocytes (typical for wildtype Siglec-5), but also on monocytes (typical for wildtype Siglec-14; Fig. 1). Thus, monocytes express different Siglec

proteins depending on the genotype: homozygous wildtype, Siglec-14 only; heterozygous, Siglec-14 and Siglec-5; homozygous *SIGLEC14*-null, the Siglec-5-like fusion protein only (Electronic supplementary material, Fig. 1c).

NTHi binds to Siglec-14 in both a sialic acid-dependent manner and a sialic acid-independent manner

Some Siglec family members (e.g., Siglec-9) interact with pathogenic bacteria that express sialic acids [40–42]. To assess if Siglecs on myeloid cells interact with NTHi, a major cause of COPD exacerbation [6], we evaluated binding of fluorescein-labeled NTHi to recombinant Siglec. NTHi bound to Siglec-14 and Siglec-5 in both a sialic acid-dependent and a sialic acid-independent manner, but exhibited only sialic acid-dependent binding to Siglec-9 (Fig. 2a). No appreciable binding of NTHi to siglec-3 or TREM1 (used as a negative control) was observed. The presence of a sialic acid-independent interaction between NTHi and Siglec-14 was confirmed by the binding of NTHi to the Arg¹¹⁹ → Ala mutant of Siglec-14 (Siglec-14 R119A), which cannot recognize sialic acids [28] (Fig. 2b).

Siglec-14 enhances proinflammatory cytokine responses elicited by NTHi

Since monocytes and macrophages are thought to play pivotal roles in COPD exacerbation [43, 44], we next evaluated the effect of Siglec-14 and Siglec-5 expression on monocytes, using as a model the THP-1 human monoblastoid cell line that expresses very low levels of endogenous Siglec-14 and Siglec-5. We introduced cDNAs for Siglec-14 and/or Siglec-5 and selected separate Siglec-14⁺5[−], Siglec-14⁺5⁺ and Siglec-14[−]5⁺ THP-1 sublines, mimicking monocytes from homozygous wildtype, heterozygous and homozygous *SIGLEC14*-null individuals, respectively (Electronic supplementary material, Fig. 1c). Exposure to NTHi in Siglec-14⁺5[−] THP-1 cells (mimicking homozygous wildtype monocytes) elicited strong release of tumor necrosis factor- α (TNF- α) and interleukin-8 (IL-8), two cytokines with an established connection to COPD exacerbation [45] (Fig. 2c, d). Progressively weaker TNF- α and IL-8 responses were seen in Siglec-14⁺5⁺ THP-1 cells (mimicking heterozygous monocytes) and Siglec-14[−]5⁺ THP-1 cells (mimicking homozygous *SIGLEC14*-null monocytes), indicating that the relative amounts of Siglec-14 and Siglec-5 influence the magnitude of proinflammatory responses.

Syk inhibitor attenuates proinflammatory cytokine responses elicited by NTHi

Since Siglec-14 associates with adapter protein DAP12 [27], downstream signaling is predicted to proceed through recruitment of the protein tyrosine kinase Syk. Consistent with this prediction, incubation of Siglec-14⁺5[−] THP-1 cells (mimicking homozygous wildtype monocytes) with R406 or BAY61-3606 (Syk-specific inhibitor) indeed blocked cytokine responses to NTHi in a dose-dependent manner (Fig. 2e, f).

***SIGLEC14*-null allele is associated with reduced risk of COPD exacerbation**

Based on these data, we hypothesized that the *SIGLEC14* genotype may influence the occurrence of COPD exacerbations secondary to NTHi infection. To evaluate this hypothesis, we genotyped 135 Japanese COPD patients with a 1-year follow-up record for exacerbations (Table 1). We defined exacerbation in the following two ways: (1) using the classic definition of Anthonisen et al. [32], to determine the incidence of exacerbations putatively caused by bacterial infection; and (2) using the new definition of Rodriguez-Roisin [33], to determine the frequency of all exacerbations. We found that *SIGLEC14* gene dosage was correlated positively with the incidence of bacterial exacerbations and the frequency of all exacerbations ($p = 0.0015$ and 0.0002 , respectively; Fig. 3a, b). Since smoking cessation, milder airflow limitation (post-bronchodilator FEV1 % predicted), and medication (inhaled corticosteroid) have each been reported to reduce the rate of COPD

exacerbations [21, 46,47], we repeated the same analyses with adjustment for each factor. Once again, we identified a significant association between *SIGLEC14* gene dosage and the incidence of bacterial exacerbations and the frequency of all exacerbations ($p = 0.0034$ and 0.0044 , respectively).

Possible correlation between *SIGLEC14* genotype and airflow limitation

We also found a negative correlation between the number of wildtype (*SIGLEC14*-positive) alleles and post-bronchodilator FEV1 % ($p = 0.0249$; Fig. 3c). This correlation was significant ($p = 0.0322$) even after correcting for age, gender, and smoking history (pack-years) as covariates. These findings imply that more frequent exacerbations in homozygous wildtype and heterozygous individuals would lead to more severe airflow limitation. Taken together, these findings support the hypothesis that infection-induced exacerbation leads to faster reduction in lung function in individuals expressing Siglec-14.

Serum concentration of soluble Siglec-14 is associated with *SIGLEC14* genotype and susceptibility to COPD exacerbation

We next examined if soluble circulating Siglec-14 can be used as a marker for COPD exacerbations. To this end, we developed a sandwich ELISA that detects Siglec-14 but not Siglec-5 (Fig. 4a), and applied this assay for quantitative measurement of soluble Siglec-14 in matched serum samples of COPD patients before and during exacerbations. The amount of serum Siglec-14 was correlated with the number ($n = 0, 1$ or 2) of wildtype alleles ($p < 0.0001$; Fig. 4b). However, we did not observe consistent changes in the concentration of serum Siglec-14 between serum samples collected before and during exacerbations ($p = 0.2$ by paired t test, and $p = 0.0784$ by sign test; Fig. 4c). These results suggest that soluble Siglec-14 is present in the serum of homozygous wildtype and heterozygous individuals and its concentration reflects the number of wildtype alleles in these individuals. However, in individual patients, the abundance of soluble Siglec-14 does not change in a strong or consistent fashion with the presence/absence of ongoing exacerbations. Nevertheless, we found that the overall serum concentration of soluble Siglec-14 was positively correlated with exacerbation frequency using the definition of Rodriguez-Roisin ($p < 0.0001$; Fig. 4d). This result reflects the fact that the *SIGLEC14* genotype is positively correlated with both Siglec-14 serum concentration and COPD exacerbation frequency.

Thus, measurement of Siglec-14 serum concentration may be used as a surrogate for *SIGLEC14* genotyping to evaluate susceptibility to COPD exacerbations. Moreover, there was a positive correlation between Siglec-14 serum concentrations and exacerbation frequency (using the definition of Rodriguez-Roisin) among homozygous wildtype and heterozygous individuals (analyzed by Poisson regression using a generalized linear model), even after *SIGLEC14* gene dosage ($n = 1$ or 2) was included as a covariate ($p = 0.0002$). In addition, there was a negative correlation between serum Siglec-14 concentrations and post-bronchodilator FEV1 % ($p = 0.0402$; Fig. 4e). These results suggest that Siglec-14 serum concentration may be a useful predictor of COPD exacerbation susceptibility and consequential decline in pulmonary function.

Discussion

We demonstrated that Siglec-14 interacts with NTHi and enhances proinflammatory responses of immune cells in a tissue culture model, and that COPD patients with wildtype (*SIGLEC14*-positive) alleles suffer more frequent exacerbations than homozygous *SIGLEC14*-null patients. A possible mechanism behind this genotype-phenotype correlation can be summarized as follows (Fig. 5): myeloid cells of COPD patients expressing Siglec-14 respond to airway infection by NTHi more strongly and produce larger amounts of

proinflammatory cytokines, which recruit inflammatory cells, eventually leading to COPD exacerbation. An additional factor may be the expression of *SIGLEC14/5* fusion gene product (identical to Siglec-5 in amino acid sequence) on monocytes of *SIGLEC14*-null allele carriers, attenuating a proinflammatory response. The expression of sialic acids by NTHi likely represents an evolutionary process with the advantage of mimicking sialic acid-based “self-associated molecular patterns” (SAMPs) [48], which are normally recognized by inhibitory Siglecs such as Siglec-5. The cross-recognition by Siglec-14 (activating counterpart) probably represents an evolutionary response of the host to this evolutionary development in the bacteria. However, in the setting of a chronic disease such as COPD, such a host response may also generate unwanted inflammation, to the detriment of the host.

COPD is a multifactorial disease with a complex etiology that is not fully understood. While tobacco smoking plays a fundamental role in COPD pathogenesis in the developed world, confounding factors, some genetic (e.g., deficiency of α_1 antitrypsin [11]) and some nongenetic (e.g., latent adenoviral infection [49]), are also involved. While many studies on host genetic factors influencing COPD pathogenesis have been conducted, those focusing on COPD exacerbations are relatively scarce. Before our study, genetic polymorphisms in four human genes (i.e., SNPs in *MBL2*, *SFTPB*, *CCL1* and *HHIP*) were associated with the risk of COPD exacerbations [16-20]. Our study adds a new entry, the first non-SNP-type polymorphism, to this very short list. It is the second mammalian lectin (the other being mannose-binding lectin encoded by the *MBL2* gene) found to be associated with the risk of COPD exacerbations, pointing to the importance of glycan recognition in the interactions between infectious agents and the immune system.

Excessive inflammatory responses to infectious agents are a putative cause of the sharp decline in pulmonary function and increased mortality during and after COPD exacerbations. At present, corticosteroids are widely used to control the inflammatory response during episodes of COPD exacerbation, but severe side effects limit their utility in long-term therapy. Our findings suggest that the use of Syk inhibitors may be beneficial in mitigating the infection-induced inflammatory response. Although one of the compounds we used (BAY61-3606) is not in clinical development, the other Syk inhibitor (R406; Rigel/AstraZeneca) has entered clinical trials as a candidate drug to treat rheumatoid arthritis [50]. Treatment with a Syk inhibitor might also be relevant in the treatment of nonhemolytic transfusion reactions (including transfusion-related acute lung injury), some of which may be caused by anti-Siglec-14 alloantibody present in transfused blood plasma [51].

Our finding that patients with wildtype alleles have more severe airflow limitation implies that individuals with a propensity for frequent exacerbations are more prone to a rapid decline in respiratory function. This logic may extend to previous findings regarding the genetic and nongenetic factors involved in COPD pathogenesis. For example, latent adenoviral infection of the respiratory system reportedly contributes to COPD pathogenesis by enhancing the inflammatory response elicited by tobacco smoke [49, 52]. Latent adenoviral infection may increase the frequency and/or intensity of exacerbations elicited by viral or bacterial infection as well, which may play a role not only in COPD pathogenesis but also in its progression.

Although we initially suspected a link between *SIGLEC14* genotype and COPD exacerbations based on the interaction between Siglec-14 and NTHi, Siglec-14 may influence inflammatory responses to other pathogens as well, and its effect on COPD exacerbations may not be limited to that caused by NTHi. For example, Siglec-14 expression on myeloid cells may generally influence the inflammatory response to acute viral infection of the airway and lung epithelia by altering cell activation thresholds, leading to COPD exacerbation [53].

The correlation between soluble Siglec-14 serum concentration and exacerbation frequency, even after correcting for wildtype allele number, was unexpected. Although it was beyond the scope of this initial work, it would be interesting to pursue a prospective study enrolling more COPD patients to examine potential correlations between Siglec-14 serum concentration and exacerbation frequency, possibly in combination with patient stratification (based on the cause of exacerbations). Such work may provide information regarding the clinical utility of Siglec-14 serum concentration for COPD exacerbation prognosis. It is also important for the mechanism(s) by which myeloid cells release soluble Siglec-14 to be elucidated.

Our study had limitations. Although the number of patients recruited was substantial ($n = 135$), the patients at our institution are uniform in ethnicity. As the frequency of the *SIGLEC14*-null allele is higher in Asia than in other regions [28], our results may be primarily relevant to Asian patients. Second, the follow-up period was limited to 1 year. However, a previous study on COPD pathophysiology showed that patients should be followed for at least 1 year to allow for seasonal effects and accurate estimation of exacerbation frequency [54]. It has also been reported that the frequency with which patients have exacerbations remains relatively stable from year to year [55].

In summary, we demonstrated that COPD patients who express Siglec-14 suffer more frequent exacerbations than those who do not. This knowledge may be utilized to stratify patient populations for personalized management, such as more intensive monitoring or earlier medical intervention against exacerbations in patients who express Siglec-14. Furthermore, Siglec-14 and its downstream signaling pathway may be promising targets for therapeutic intervention to treat COPD exacerbations and limit disease progression.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Leela Davies, Xiaoxia Wang and Mina Fujishiro for experimental help, Andrea Verhagen and Sandra Diaz for general laboratory help, and Syed Raza Ali for general discussion. We also thank Dr. Michael A. Apicella (University of Iowa) for the generous gift of NTHi strain 2019. This work was supported by Global COE program “Frontier Biomedical Science Underlying Organelle Network” from the Ministry of Education, Culture, Sports, Science and Technology of Japan to Osaka University (to T.A. and N.T.); the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), Japan (to K.K. and N.T.); and the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) Programs of Excellence in Glycosciences (P01HL107150 to A.V. and V.N.).

References

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007; 176:532–555. [PubMed: 17507545]
2. World Health Organization. World Health Statistics 2008. WHO; Geneva: 2008.
3. Chenna PR, Mannino DM. Outcomes of severe COPD exacerbations requiring hospitalization. *Semin Respir Crit Care Med*. 2010; 31:286–294. [PubMed: 20496298]
4. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. *Thorax*. 2011; 66:585–590. [PubMed: 21515553]
5. Decramer M, Nici L, Nardini S, Reardon J, Rochester CL, Sanguinetti CM, Troosters T. Targeting the COPD exacerbation. *Respir Med*. 2008; 102(suppl 1):S3–S15. [PubMed: 18582795]

6. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med.* 2002; 347:465–471. [PubMed: 12181400]
7. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med.* 2008; 359:2355–2365. [PubMed: 19038881]
8. Barnes PJ. New treatments for COPD. *Nat Rev Drug Discov.* 2002; 1:437–446. [PubMed: 12119745]
9. Brinkman RR, Dube MP, Rouleau GA, Orr AC, Samuels ME. Human monogenic disorders—a source of novel drug targets. *Nat Rev Genet.* 2006; 7:249–260. [PubMed: 16534513]
10. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. *Nat Rev Genet.* 2009; 10:872–878. [PubMed: 19859063]
11. Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. *Scand J Clin Lab Invest.* 1967; 19:205–208. [PubMed: 6048625]
12. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. *Thorax.* 1999; 54:693–696. [PubMed: 10413721]
13. Molino NA. Genetics of COPD. *Chest.* 2004; 125:1929–1940. [PubMed: 15136409]
14. Hersh CP, Demeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. *Am J Respir Cell Mol Biol.* 2005; 33:71–78. [PubMed: 15817713]
15. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genet.* 2009; 5:e1000421. [PubMed: 19300482]
16. Foreman MG, DeMeo DL, Hersh CP, Carey VJ, Fan VS, Reilly JJ, Shapiro SD, Silverman EK. Polymorphic variation in surfactant protein B is associated with COPD exacerbations. *Eur Respir J.* 2008; 32:938–944. [PubMed: 18550614]
17. Lin CL, Siu LK, Lin JC, Liu CY, Chian CF, Lee CN, Chang FY. Mannose-binding lectin gene polymorphism contributes to recurrence of infective exacerbation in patients with COPD. *Chest.* 2011; 139:43–51. [PubMed: 20688922]
18. Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. *Genes Immun.* 2003; 4:269–274. [PubMed: 12761563]
19. Takabatake N, Shibata Y, Abe S, et al. A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2006; 174:875–885. [PubMed: 16864713]
20. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010; 182:1498–1505. [PubMed: 20656943]
21. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med.* 2010; 363:1128–1138. [PubMed: 20843247]
22. Hood DW, Makepeace K, Deadman ME, Rest RF, Thibault P, Martin A, Richards JC, Moxon ER. Sialic acid in the lipopolysaccharide of *Haemophilus influenzae*: strain distribution, influence on serum resistance and structural characterization. *Mol Microbiol.* 1999; 33:679–692. [PubMed: 10447878]
23. Mandrell RE, McLaughlin R, Aba Kwaik Y, Lesse A, Yamasaki R, Gibson B, Spinola SM, Apicella MA. Lipooligosaccharides (LOS) of some *haemophilus* species mimic human glycosphingolipids, and some LOS are sialylated. *Infect Immun.* 1992; 60:1322–1328. [PubMed: 1372291]
24. Angata T, Varki A. Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. *Chem Rev.* 2002; 102:439–470. [PubMed: 11841250]
25. Varki A, Angata T. Siglecs – the major subfamily of I-type lectins. *Glycobiology.* 2006; 16:1R–27R. [PubMed: 16118287]
26. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol.* 2007; 7:255–266. [PubMed: 17380156]

27. Angata T, Hayakawa T, Yamanaka M, Varki A, Nakamura M. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. *FASEB J.* 2006; 20:1964–1973. [PubMed: 17012248]
28. Yamanaka M, Kato Y, Angata T, Narimatsu H. Deletion polymorphism of SIGLEC14 and its functional implications. *Glycobiology.* 2009; 19:841–846. [PubMed: 19369701]
29. Greiner LL, Watanabe H, Phillips NJ, Shao J, Morgan A, Zaleski A, Gibson BW, Apicella MA. Nontypeable *Haemophilus influenzae* strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans. *Infect Immun.* 2004; 72:4249–4260. [PubMed: 15213170]
30. Taylor RE, Gregg CJ, Padler-Karavani V, et al. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. *J Exp Med.* 2010; 207:1637–1646. [PubMed: 20624889]
31. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, Kumagai H. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. *Exp Hematol.* 2003; 31:1007–1014. [PubMed: 14585362]
32. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med.* 1987; 106:196–204. [PubMed: 3492164]
33. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. *Chest.* 2000; 117:398S–401S. [PubMed: 10843984]
34. American Thoracic Society. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med.* 1995; 152:1107–1136. [PubMed: 7663792]
35. Japanese Respiratory Society. The predicted values of spirometry and arterial blood gas analysis in Japanese. *J Jpn Respir Soc.* 2001; 39:1–17.
36. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. *Am J Respir Crit Care Med.* 2000; 162:1102–1108. [PubMed: 10988137]
37. Okazawa M, Muller N, McNamara AE, Child S, Verburgt L, Pare PD. Human airway narrowing measured using high resolution computed tomography. *Am J Respir Crit Care Med.* 1996; 154:1557–1562. [PubMed: 8912780]
38. Orlandi I, Moroni C, Camiciottoli G, Bartolucci M, Pistolesi M, Villari N, Mascalchi M. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. *Radiology.* 2005; 234:604–610. [PubMed: 15671010]
39. Firth D. Bias reduction of maximum likelihood estimates. *Biometrika.* 1993; 80:27–38.
40. Jones C, Virji M, Crocker PR. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. *Mol Microbiol.* 2003; 49:1213–1225. [PubMed: 12940982]
41. Carlin AF, Lewis AL, Varki A, Nizet V. Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. *J Bacteriol.* 2007; 189:1231–1237. [PubMed: 16997964]
42. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. *Blood.* 2009; 113:3333–3336. [PubMed: 19196661]
43. Barnes PJ. Alveolar macrophages as orchestrators of COPD. *COPD.* 2004; 1:59–70. [PubMed: 16997739]
44. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. *Lancet.* 2009; 374:744–755. [PubMed: 19716967]
45. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2001; 163:349–355. [PubMed: 11179105]
46. Au DH, Bryson CL, Chien JW, Sun H, Udris EM, Evans LE, Bradley KA. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. *J Gen Intern Med.* 2009; 24:457–463. [PubMed: 19194768]

47. Alsaeedi A, Sin DD, Mcalister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. *Am J Med.* 2002; 113:59–65. [PubMed: 12106623]
48. Varki A. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. *Glycobiology.* 2011; 21:1121–1124. [PubMed: 21932452]
49. Hogg JC. Role of latent viral infections in chronic obstructive pulmonary disease and asthma. *Am J Respir Crit Care Med.* 2001; 164:S71–S75. [PubMed: 11734471]
50. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Engl J Med.* 2010; 363:1303–1312. [PubMed: 20879879]
51. Yasui K, Angata T, Matsuyama N, Furuta RA, Kimura T, Okazaki H, Tani Y, Nakano S, Narimatsu H, Hirayama F. Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions. *Br J Haematol.* 2011; 153(6):794–796. [PubMed: 21477167]
52. Hayashi S, Hogg JC. Adenovirus infections and lung disease. *Curr Opin Pharmacol.* 2007; 7:237–243. [PubMed: 17446135]
53. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2004; 1:115–120. [PubMed: 16113423]
54. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. *Eur Respir J.* 1999; 13:844–849. [PubMed: 10362051]
55. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. *Eur Respir J.* 2003; 22:931–936. [PubMed: 14680081]

Fig. 1.

Expression of *SIGLEC14/5* fusion gene product. Peripheral blood leukocytes from homozygous *SIGLEC14*-null individuals were analyzed by flow cytometry. *Gray shaded areas* cells stained with a negative control antibody (IC002A, R&D Systems). *Solid lines* cells stained with antibody recognizing both Siglec-5 and Siglec-14 (FAB10721A, R&D Systems). *SIGLEC14/5* fusion gene product, which is identical to Siglec-5 in amino acid sequence, is expressed on granulocytes, monocytes, and B lymphocytes

Fig. 2.

Influence of Siglec-14 and Siglec-5 expression on inflammatory responses. **a** Binding of NTHi to human myeloid Siglecs. Both sialic acid-positive (*solid bars*) and sialic acid-negative (*open bars*) NTHi bound to Siglec-5 and Siglec-14, whereas only sialic acid-positive NTHi bound to Siglec-9. Background fluorescence (autofluorescence of assay buffer) was subtracted. $*p < 0.05$ by one-way ANOVA followed by Dunnett's multiple comparison test, vs. "none" within each group. **b** Binding of NTHi to Siglec-14 wildtype and R119A mutant. Both sialic acid-positive NTHi (*solid bars*) and sialic acid-negative NTHi (*open bars*) showed binding to both wildtype Siglec-14 and the R119A mutant. Background fluorescence (autofluorescence of assay buffer) was subtracted. $*p < 0.05$ by

two-way ANOVA followed by Bonferroni multiple comparison test (four pairwise comparisons: Siglec-14 wildtype, sialic acid-negative vs. sialic acid-positive NTHi; Siglec-14 R119A, sialic acid-negative vs. sialic acid-positive NTHi; sialic acid-negative NTHi, Siglec-14 wildtype vs. R119A; sialic acid-positive NTHi, Siglec-14 wildtype vs. R119A). **a, b** Measurements performed in triplicate wells and repeated at least three times independently. Consistent results were obtained, and representative data are shown. Values shown are means $\pm$ standard error of the mean (SEM). **c, d** IL-8 production (**c**) and TNF- α production (**d**) from THP-1 sublines stimulated with NTHi (*solid bars* THP-1 cells mimicking homozygous wildtype monocytes, *gray bars* THP-1 cells mimicking heterozygous monocytes, *open bars* THP-1 cells mimicking homozygous *SIGLEC14*-null monocytes). * $p < 0.05$ by one-way ANOVA followed by Bonferroni's multiple comparison test (three pairwise comparisons). **e, f** IL-8 production (**e**) and TNF- α production (**f**) from Siglec-14⁺5⁻ THP-1 subline stimulated with NTHi in the presence of R406 (*open circles*) or BAY61-3606 (*closed circles*). * $p < 0.05$ by one-way ANOVA followed by Dunnett's multiple comparison test (vs. vehicle control = "0 μ M", within each treatment group). **c-f** Measurements were performed in quadruplicate wells and repeated four times independently with consistent results, and representative data are shown. All values shown are means $\pm$ SEM

Fig. 3.

Effect of *SIGLEC14* genotype on the frequency of COPD exacerbations. **a** *SIGLEC14* genotype and the incidence of bacterial exacerbations using the definition of Anthonisen et al. [32] (*without EX* patients without bacterial exacerbations, *with EX* patients with one or more incidences). **b** *SIGLEC14* genotype and the frequency of all exacerbations using the definition of Rodriguez-Roisin. Values are means $\pm$ standard deviation. **c** *SIGLEC14* genotype and severity of airflow obstruction (post-bronchodilator FEV1 %). Each point represents an individual patient (*Wild* homozygous wildtype, *Hetero* heterozygous, *Null* homozygous *SIGLEC14*-null)

Fig. 4.

Correlation between *SIGLEC14* genotype, serum Siglec-14, and COPD exacerbations. **a** Siglec-14-Fc (solid circles) and Siglec-5-Fc (open circles), serially diluted from 100 to 1.5625 ng/ml, were analyzed using a sandwich ELISA specific for Siglec-14 as described in Materials and Methods. Values are means $\pm$ SEM. **b** Correlations between serum Siglec-14 and *SIGLEC14* genotype. Siglec-14 serum concentrations on average reflect the number of wildtype (*SIGLEC14*-positive) alleles. **c** The Siglec-14 serum concentrations in COPD patient sera before and during exacerbation. The lines connect Siglec-14 concentrations in samples collected before and during exacerbations (stable and exacerbation, respectively) from the same individuals ($n = 21$; homozygous wildtype and heterozygous patients only). **d**

Correlations between Siglec-14 serum concentrations and frequency of exacerbations (using the definition of Rodriguez-Roisin). **e** Correlation between Siglec-14 serum concentrations and post-bronchodilator FEV1 %

Fig. 5.

Possible mechanism behind the correlation between *SIGLEC14* genotype and COPD exacerbation-prone phenotype. The wildtype (*SIGLEC14*-positive) allele confers expression of Siglec-14 on monocytes, while the *SIGLEC14*-null (*SIGLEC14/5* fusion) allele confers expression of Siglec-5. Monocytes of homozygous wildtype individuals express Siglec-14 only, those of heterozygous individuals both Siglec-14 and Siglec-5, and those of homozygous *SIGLEC14*-null individuals Siglec-5 only. Siglec-14 associates with adapter protein DAP12 and the tyrosine kinase Syk to transduce cell-activating signal upon engagement. Siglec-5, on the other hand, associates with tyrosine phosphatase SHP-1 to transduce a cell-inhibitory signal. The myeloid cells of those who carry the wildtype allele respond strongly to infectious cues, while those of homozygous *SIGLEC14*-null individuals respond weakly. Excessive proinflammatory responses in COPD patients lead to exacerbation

Table 1Basic characteristics and *SIGLEC14* genotypes of subjects

	<i>SIGLEC14</i> genotype		
	Wildtype (<i>n</i> = 33)	Heterozygote (<i>n</i> = 71)	Null (<i>n</i> = 31)
Age	71.8 ± 8.2	72.3 ± 7.5	73.7 ± 8.8
Gender (<i>n</i>)			
Male	30	69	29
Female	3	2	2
Smoking status at the time of enrollment			
Ex (<i>n</i>)	31	70	29
Current (<i>n</i>)	2	1	2
Pack-years	79.9 ± 60.7	74.7 ± 44.8	68.0 ± 37.2
Pulmonary function tests			
VC (l)	3.11 ± 0.91	3.32 ± 0.91	3.10 ± 0.88
% VC (%)	90.8 ± 23.0	96.1 ± 19.5	91.2 ± 18.5
FEV1 (l)	1.49 ± 0.68	1.56 ± 0.67	1.58 ± 0.54
FEV1% (%)	47.3 ± 11.7	47.5 ± 12.4	52.9 ± 9.3
FEV1 % predicted (%)	55.2 ± 21.5	57.8 ± 21.6	60.3 ± 16.6
RV/TLC (%)	51.2 ± 10.9	47.9 ± 10.6	47.9 ± 8.1
% DLCO/VA (%)	58.3 ± 27.8	56.6 ± 20.3	68.0 ± 23.2
Computed tomography			
Low attenuation area (%)	32.8 ± 13.1	35.1 ± 15.0	30.1 ± 11.2
Therapy (%)			
Long-acting beta agonist	88.0	84.6	77.8
Long-acting muscarinic antagonist	84.0	92.3	81.5
Inhaled corticosteroid	68.0	73.9	69.2
Systemic corticosteroid	0	0	0

The values shown are means ± standard deviation. There were no significant differences between the groups regarding any of the parameters shown. *VC* vital capacity; % *VC* actual/predicted *VC* ratio, in percentage; *FEV1*% FEV1/FVC ratio, in percentage; *FEV1 % predicted* actual/predicted FEV1 ratio, in percentage; *RV/TLC* residual volume/total lung capacity; %*DLCO/VA* diffusing capacity for carbon monoxide/alveolar volume, in percentage